CITIC Securities: First therapeutic HPV vaccine approved; AI accelerates vaccine development.

Citic Securities research report stated that the first therapeutic HPV vaccine PRGN-2012 has been approved for market launch, filling the treatment gap in the RRP field, and also boosting the prospects of the innovative therapeutic vaccine industry. Overseas therapeutic vaccine pipeline progress is in full swing, with multiple technology platforms flourishing. Important data is expected to be released in the near future and in the next 1-2 years, leading the industry into an intensive catalytic phase. With the empowerment of AI, antigen design efficiency will further improve, and vaccine research and production are expected to accelerate. It is recommended to pay attention to relevant targets in the layout of therapeutic vaccines.